Active Not Recruiting NA INTERVENTIONAL 2-arm NCT03881605

MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC (SYMPToM)

Routine MRI Screening Versus Symptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative and HER2+ Metastatic Breast Cancer (MBC): a Single-centre Randomized Pilot Study

Sponsor: Harvard University

Conditions Brain Metastases Breast Neoplasm HER2-positive Breast Cancer Triple Negative Breast Cancer

Interventions MRI screening

Updated 6 times since 2019 Last updated: Jan 17, 2025 Started: Nov 8, 2018 Primary completion: Dec 31, 2025 Completion: Dec 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Brain Metastases and Breast Neoplasm, this trial is ongoing. The trial is conducted by Harvard University and has accumulated 6 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Feb 2025 — Present [monthly]

Active Not Recruiting NA

Status: Unknown → Active Not Recruiting
Sep 2024 — Feb 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting NA

▶ Show 1 earlier version

Apr 2019 — Jan 2021 [monthly]

Recruiting NA

First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harvard University
Sunnybrook Health Sciences Centre

Data source: Sunnybrook Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada